Alemtuzumab induces changes in the innate immune system in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Ladwig, A. [1 ]
Suh, J. [1 ]
Schweitzer, F. [1 ]
Roeth, P. [1 ]
Remke, G. [1 ]
Warnke, C. [1 ]
Schroeter, M. [1 ]
Izquierdo-Alvarez, E. [1 ]
Bonmann, E. [2 ]
Fink, G. R. [1 ]
Pallasch, C. [1 ]
Lehmann, H. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Merheim Hosp, Cologne, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0287
引用
收藏
页码：259 / 259
页数：1
相关论文
共 50 条
  • [21] Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanisms
    Oreja-Guevara, C.
    Ramos Cejudo, J.
    Stark, L.
    Martin Ibanez, N.
    Rodriguez de Antonio, L.
    Chamorro, B.
    Diez-Tejedor, E.
    JOURNAL OF NEUROLOGY, 2011, 258 : 255 - 256
  • [22] Alemtuzumab induces severe orbitopathy in relapsing–remitting multiple sclerosis
    Pablo Rodríguez de Vera Gómez
    Mariola Méndez Muros
    Alberto Torres Cuadro
    Francisco Javier Toyos Sáenz de Miera
    Rocío López Ruiz
    Raquel Guerrero Vázquez
    Juan Jesús García González
    Antonio Manuel Garrido Hermosilla
    Tomás Martín Hernández
    Journal of Neurology, 2024, 271 : 486 - 496
  • [23] Alemtuzumab Induces a Sustained Reduction in Disability in Patients with Relapsing Remitting Multiple Sclerosis
    Coles, Alasdair J.
    NEUROLOGY, 2009, 72 (11) : A318 - A318
  • [24] ALEMTUZUMAB BUDGET IMPACT ANALYSIS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE US
    Celestin, C.
    Wandstrat, T.
    Coleman, C., I
    VALUE IN HEALTH, 2015, 18 (03) : A280 - A280
  • [25] Innate Immune System and Multiple Sclerosis. Granulocyte Numbers Are Reduced in Patients Affected by Relapsing-Remitting Multiple Sclerosis during the Remission Phase
    Pavelek, Zbysek
    Angelucci, Francesco
    Soucek, Ondrej
    Krejsek, Jan
    Sobisek, Lukas
    Klimova, Blanka
    Sarlakova, Jana
    Haluskova, Simona
    Kuca, Kamil
    Valis, Martin
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (05)
  • [26] Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis
    Iovino, Aniello
    Aruta, Francesco
    Carotenuto, Antonio
    Manganelli, Fiore
    Iodice, Rosa
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 28 : 98 - 100
  • [27] Alemtuzumab and Thyroid Autoimmunity in Relapsing-Remitting Multiple Sclerosis Patients in CAMMS223
    Brinar, Vesna
    NEUROLOGY, 2011, 76 (09) : A246 - A246
  • [28] Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis is independent of baseline status
    Coles, A. J.
    JOURNAL OF NEUROLOGY, 2007, 254 : 55 - 55
  • [29] Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Zimmermann, J.
    Buhl, T.
    Mueller, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 382 - 382
  • [30] Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated With fingolimod
    Maria Cabrera-Maqueda, Jose
    Fuentes Rumi, Luna
    Valero Lopez, Gabriel
    Alba Isasi, Teresa
    Hernandez-Clares, Rocio
    Carreon Guarnizo, Ester
    Jimenez Veiga, Judith
    Iniesta-Martinez, Francisca
    Leon-Hernandez, Aida
    Zamarro Parra, Joaquin
    Morales Ortiz, Ana
    Meca Lallana, Jose
    NEUROLOGY, 2019, 92 (15)
12345